Anaplastic nephroblastomas express transketolase-like enzyme 1

Area of Science:

• Oncology
• Biochemistry
• Pathology

Background:

• Transketolase-like enzyme 1 (TKTL1) is a glycolytic enzyme implicated in tumor progression.
• Nephroblastoma, a common pediatric kidney cancer, generally has a good prognosis, but anaplastic forms are more aggressive.

Purpose of the Study:

• To investigate the immunoexpression of TKTL1 in anaplastic versus non-anaplastic nephroblastomas.
• To determine if TKTL1 expression correlates with the presence of anaplasia in nephroblastomas.

Main Methods:

• Analysis of archival formalin-fixed paraffin-wax-embedded tissue sections from 28 nephroblastoma patients.
• Immunohistochemical staining using a monoclonal TKTL1 antibody.

Main Results:

• TKTL1 staining was observed in 80-100% of tumor cells in 6 out of 15 anaplastic nephroblastomas.
• None of the 13 non-anaplastic nephroblastomas exhibited TKTL1 staining in over 80% of tumor cells.

Conclusions:

• TKTL1 expression is significantly associated with the presence of anaplasia in nephroblastomas.
• TKTL1 may facilitate the survival of anaplastic tumor cells under specific conditions.
• Glycolytic inhibitors could be a potential therapeutic strategy for anaplastic nephroblastomas.